Search

Your search keyword '"Jazaeri, Amir A."' showing total 209 results

Search Constraints

Start Over You searched for: Author "Jazaeri, Amir A." Remove constraint Author: "Jazaeri, Amir A." Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
209 results on '"Jazaeri, Amir A."'

Search Results

4. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance

6. Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery.

9. Clinical and genomic landscape of RAS mutations in gynecologic cancers

11. Abstract A077: The utility of surgical minimal residual disease after frontline treatment for prognostic and investigational opportunities in advanced ovarian cancer

12. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma

13. Phase 1b Study of Batiraxcept (AVB-S6-500) in Combination with Durvalumab (MEDI4736) in Patients with Platinum-Resistant Ovarian Cancer

14. Phase II Trial of Pembrolizumab in Combination with Chemotherapy for Frontline Treatment of Advanced Epithelial Ovarian Cancer

16. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.

19. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer

20. 1045 Overcoming immunosuppressive tumors by stimulating the adaptive and innate immune systems

21. Transforming ovarian cancer care by targeting minimal residual disease

22. SO013/#983 Intraoperative identification of ovarian cancer during tumor reductive surgery using the hand-held masspec pen technology

23. EP159/#1534 Leveraging personalized circulating tumor DNA monitoring to predict treatment response and recurrence in high-risk endometrial cancer

26. Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.

27. Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.

28. Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report

29. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers

30. Abstract CT122: A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube

31. Supplemental Tables from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers

32. Data from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers

33. Abstract 5473: Genomic profiling of chemotherapy-related clonal hematopoiesis in patients with high-grade serous ovarian cancer

34. Supplemental Table Legends from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers

35. Supplementary Data from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers

44. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance

45. Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies

46. Figure_S6 from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

47. Supplementary Figure S1 from Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers

48. Data from Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer

49. Supplementary Tables from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

50. Article Figures 1-4 from Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers

Catalog

Books, media, physical & digital resources